NOVEMBER 23(WED) – 25(FRI) BANGKOK, THAILAND
The abstract acceptance has been announced on
email. If you have not received an email, please check your junk or spam folder, or contact us at email@example.com
1 JULY 2022
15 SEPTEMBER 2022
16 SEPTEMBER 2022
Allergic eye diseases
Basic corneal research
Keratoplasty and keratoprosthesis
Other anterior segment surgery
Dry eye disease and Meibomian gland dysfunction
Limbal stem cell and ocular surface reconstruction
Other ocular surface diseases
Keratoconus and other ectatic diseases
CLICK TO ZOOM
In the case where research expenses are supported or free research materials (including devices) or services (including sample measurements) are provided by companies (*) through the organization to which the author belongs. (*) Companies denote both related companies and competitor companies. This is also the case for all subsequent categories.
In the case where the author is an investor in a company related to the chemicals and materials (including devices) used and services are provided.
In the case where the author is an employee of an interested company.
In the case where the author is currently, or was within the past three years, a consultant of an interested company.
In the case where the author holds a patent or is in the process of applying for a patent.
In the case where the author receives rewards (*) or travel expenses from a company related to the chemicals and materials (including devices) used and services provided.
(*) Rewards include salaries, travel fees, intellectual property rights, royalties, honoraria, shares, stock options, consultancy fees, lecture fees, expenses as a member of advisory committees and review panels, etc.
* Conflict of interest should be disclosed for the fiscal year during the previous three years when the author received the largest sum of money.
The presence or absence of conflict of interest to be disclosed for the author (including co-authors) will be automatically shown at the end of the abstract.
If the authors have to disclose any conflict of interest, the category and company names* should be described after the authors' names in the second slide and at the end of the poster.
* In the case of "Category P" (the author holds a patent or is in the process of applying for a patent), the company name need not to described.
If all authors do not have any conflict of interest to disclose, there will be a statement to the effect, “there is no conflict of interest to be disclosed".
Thank you for your cooperation. Please contact the conference secretariat for any questions by email or FAX (not by telephone).
"Names" and "contact addresses" provided to us at registration for the meeting shall be used for the purpose of contact from the secretariat, notification of acceptance or rejection, and any information related to the presentation. In addition, the “presenters' names," “affiliation names," “title" and “abstract text" shall be used for publication in the program/proceedings and on the website, but not for other purposes. The registration process for applications has been commissioned to c/o Congress Corporation in order to facilitate management operations.
When you submit your abstract, you will be asked to tick the following declarations:
Acknowledgement of the receipt of abstract submission will be sent to the Presenting Author’s email address upon submission. The Presenting Author will receive all correspondence regarding the abstract status, presentation type, date and time, via the email that is provided in the abstract submission.
The decision of Scientific Program Committee on abstract acceptance is final. While authors’ preferences for oral or poster presentations will be considered, the committee may offer an alternative format.
Should there be any inquiry, please do not hesitate to contact the 8 th Asia Cornea Society Biennial Scientific Meeting’s Scientific Committee at firstname.lastname@example.org